J Cont Med A Dent. September-December 2018;6(3):9-11.

Delamanid- A Relatively New Anti-Tuberculosis Drug

Kishor A Bansod, Mohammed Shakeel Mohammed Bashir, Tanveer Khan

Dr. Kishor A Bansod. Associate Professor, Department of Pharmacology, Dr. Punjabrao Deshmukh Medical College, Amravati, MS. <u>kishorbansod74@gmail.com</u> +919823255396

Abstract

Background: Tuberculosis (TB) is a global health problem which occurs in every part of the world. It is a curable and preventable bacterial infectious disease caused by Mycobacterium tuberculosis, still it is prevalent. Emergence of MDR and XDR-TB made the picture more complicated. Hence search for new drugs are going on to address the problem. Delamanid is a relatively new drug developed to tackle the situation. Methods: Medline database was searched using the keywords like Delamanid, Tuberculosis, New anti TB drugs, Multi drug resistant tuberculosis (MDR-TB), XDR-TB to find out the articles related with Delamanid. Results: The literature indicates that Delamanid is a good drug along with other appropriate anti TB drugs for the management of multi drug resistant tuberculosis. Conclusion: Delamanid in the dose of 100mg twice daily along with other appropriate anti TB drugs is recommended for the management of pulmonary multi drug resistant tuberculosis. It is relatively safe drug as have less adverse drug reactions and drug interactions.